

Jarno Hoekman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3744386/publications.pdf>

Version: 2024-02-01

52
papers

2,330
citations

361296

20
h-index

223716

46
g-index

52
all docs

52
docs citations

52
times ranked

2532
citing authors

#	ARTICLE	IF	CITATIONS
1	Pre-approval and post-approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2169-2179.	1.1	5
2	Four scenarios for the future of medicines and social policy in 2030. <i>Drug Discovery Today</i> , 2022, 27, 2252-2260.	3.2	5
3	Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England. <i>Value in Health</i> , 2022, 25, 390-399.	0.1	8
4	Regulatory Safety Learning Driven by the Mechanism of Action: The Case of TNF- α Inhibitors. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 123-131.	2.3	4
5	Estimation of manufacturing development costs of cell-based therapies: a feasibility study. <i>Cytotherapy</i> , 2021, 23, 730-739.	0.3	12
6	Signals from the Dutch national spontaneous reporting system: Characteristics and regulatory actions. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1115-1122.	0.9	5
7	Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies. <i>Clinical and Translational Science</i> , 2021, 14, 1566-1577.	1.5	10
8	Comprehensive evaluation of post-approval regulatory actions during the drug lifecycle – a focus on benefits and risks. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-10.	1.0	3
9	The importance of geographical distance to different types of R&D collaboration in the pharmaceutical industry. <i>Industry and Innovation</i> , 2020, 27, 513-537.	1.7	21
10	In-Hospital Production of Medicines: Preparing for Disruption. <i>Trends in Biotechnology</i> , 2020, 38, 1045-1047.	4.9	5
11	What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings. <i>Cytotherapy</i> , 2020, 22, 388-397.	0.3	29
12	Advanced therapy medicinal product manufacturing under the hospital exemption and other exemption pathways in seven European Union countries. <i>Cytotherapy</i> , 2020, 22, 592-600.	0.3	18
13	Publication rates and reported results in a cohort of gene- and cell-based therapy trials. <i>Regenerative Medicine</i> , 2020, 15, 1215-1227.	0.8	2
14	A typology of scientific breakthroughs. <i>Quantitative Science Studies</i> , 2020, 1, 1203-1222.	1.6	13
15	Development and Regulation of Gene and Cell-Based Therapies in Europe: A Quantification and Reflection. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 67-71.	4.0	5
16	Regulating advanced therapy medicinal products through the Hospital Exemption: an analysis of regulatory approaches in nine EU countries. <i>Regenerative Medicine</i> , 2020, 15, 2015-2028.	0.8	7
17	The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs. <i>International Journal of Health Policy and Management</i> , 2020, , .	0.5	8
18	Postauthorization Changes to Specific Obligations of Conditionally Authorized Medicines in the European Union: A Retrospective Cohort Study. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 426-435.	2.3	12

#	ARTICLE	IF	CITATIONS
19	The geography of scientific citations. <i>Research Policy</i> , 2019, 48, 1771-1780.	3.3	24
20	Changing standards for drug approval: A longitudinal analysis of conditional marketing authorisation in the European Union. <i>Social Science and Medicine</i> , 2019, 222, 76-83.	1.8	14
21	A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making. <i>Cytotherapy</i> , 2018, 20, 769-778.	0.3	23
22	EU decision-making for marketing authorization of advanced therapy medicinal products: a case study. <i>Drug Discovery Today</i> , 2018, 23, 1328-1333.	3.2	24
23	Global Regulatory Differences for Gene and Cell-Based Therapies: Consequences and Implications for Patient Access and Therapeutic Innovation. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 120-127.	2.3	22
24	Organizational capacities of national pharmacovigilance centres in Africa: assessment of resource elements associated with successful and unsuccessful pharmacovigilance experiences. <i>Globalization and Health</i> , 2018, 14, 109.	2.4	27
25	Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe. <i>Molecular Therapy - Methods and Clinical Development</i> , 2018, 11, 121-130.	1.8	63
26	The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative study. <i>BMC Public Health</i> , 2018, 18, 1384.	1.2	11
27	Factors related to drug approvals: predictors of outcome?. <i>Drug Discovery Today</i> , 2017, 22, 937-946.	3.2	8
28	What drives university research performance? An analysis using the CWTS Leiden Ranking data. <i>Journal of Informetrics</i> , 2017, 11, 859-872.	1.4	60
29	FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines. <i>Frontiers in Pharmacology</i> , 2017, 8, 161.	1.6	21
30	Characteristics and follow-up of postmarketing studies of conditionally authorized medicines in the EU. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 213-226.	1.1	42
31	Accelerating access to new medicines: Current status of facilitated regulatory pathways used by emerging regulatory authorities. <i>Journal of Public Health Policy</i> , 2016, 37, 315-333.	1.0	17
32	Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase®. <i>Drug Safety</i> , 2016, 39, 335-345.	1.4	119
33	Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 758-768.	0.8	29
34	Does conditional approval for new oncology drugs in Europe lead to differences in health technology assessment decisions?. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 489-491.	2.3	31
35	Use of the conditional marketing authorization pathway for oncology medicines in Europe. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 534-541.	2.3	49
36	Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2055-2064.	3.0	204

#	ARTICLE	IF	CITATIONS
37	An analysis of marketing authorisation applications via the mutual recognition and decentralised procedures in Europe. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1237-1244.	0.8	7
38	Spatial Scientometrics and Scholarly Impact: A Review of Recent Studies, Tools, and Methods. , 2014, , 127-146.		18
39	A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 434-441.	0.8	19
40	Predictors of Congestive Heart Failure after Treatment with an Endothelin Receptor Antagonist. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 490-498.	2.2	24
41	Big Pharma, little science?. <i>Technological Forecasting and Social Change</i> , 2014, 81, 22-38.	6.2	105
42	The Importance of Short-Term Off-Target Effects in Estimating the Long-Term Renal and Cardiovascular Protection of Angiotensin Receptor Blockers. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 208-215.	2.3	24
43	The Use of Surrogate Endpoints in Regulating Medicines for Cardio-Renal Disease: Opinions of Stakeholders. <i>PLoS ONE</i> , 2014, 9, e108722.	1.1	11
44	Acquisition of European research funds and its effect on international scientific collaboration. <i>Journal of Economic Geography</i> , 2013, 13, 23-52.	1.6	83
45	Proximity and Stratification in European Scientific Research Collaboration Networks: A Policy Perspective. <i>Advances in Spatial Science</i> , 2013, , 263-277.	0.3	3
46	The Geographical Distribution of Leadership in Globalized Clinical Trials. <i>PLoS ONE</i> , 2012, 7, e45984.	1.1	31
47	Big Pharma, Little Science? A Bibliometric Perspective on Big Pharma's R&D Decline. <i>SSRN Electronic Journal</i> , 2012, , .	0.4	5
48	European infrastructure networks and regional innovation in science-based technologies. <i>Economics of Innovation and New Technology</i> , 2011, 20, 517-537.	2.1	12
49	Research collaboration at a distance: Changing spatial patterns of scientific collaboration within Europe. <i>Research Policy</i> , 2010, 39, 662-673.	3.3	395
50	The geography of collaborative knowledge production in Europe. <i>Annals of Regional Science</i> , 2009, 43, 721-738.	1.0	395
51	Spatial scientometrics: Towards a cumulative research program. <i>Journal of Informetrics</i> , 2009, 3, 222-232.	1.4	223
52	CONVERGENCE IN AN ENLARGED EUROPE: THE ROLE OF NETWORK CITIES. <i>Tijdschrift Voor Economische En Sociale Geografie</i> , 2006, 97, 321-326.	1.2	15